Caring for two in the ICU: pharmacologic management of pregnancy-related complications.
Mojdeh S HeavnerMichaelia D CucciBrooke BarlowCarolyn Magee BellClaire C EngGrace ErdmanMatthew LiSusan Elizabeth SmithMohammed AldhaeefiMelissa L Thompson BastinW Anthony HawkinsChristina RoseAllison LankfordPublished in: Pharmacotherapy (2023)
Maternal mortality continues to be an issue globally despite advances in technology and pharmacotherapy. Pregnancy can lead to complications that necessitate immediate action to prevent severe morbidity and mortality. Patients may need escalation to the ICU setting for close monitoring and administration of advanced therapies not available elsewhere. Obstetric emergencies are rare but high-stakes events that require clinicians to have prompt identification and management. The purpose of this review is to describe complications of pregnancy and provide a focused resource of pharmacotherapy considerations that clinicians may encounter. For each disease state, the epidemiology, pathophysiology, and management are summarized. Brief descriptions of non-pharmacological (e.g., cesarean or vaginal delivery of the baby) interventions are provided. Mainstays of pharmacotherapy highlighted include oxytocin for obstetric hemorrhage, methotrexate for ectopic pregnancy, magnesium and antihypertensive agents for preeclampsia and eclampsia, eculizumab for atypical hemolytic uremic syndrome, corticosteroids and immunosuppressive agents for thrombotic thrombocytopenic purpura, diuretics, metoprolol and anticoagulation for peripartum cardiomyopathy, and pulmonary vasodilators for amniotic fluid embolism.
Keyphrases
- pregnancy outcomes
- preterm birth
- pregnant women
- risk factors
- early onset
- intensive care unit
- smoking cessation
- newly diagnosed
- type diabetes
- blood pressure
- ejection fraction
- pulmonary hypertension
- end stage renal disease
- palliative care
- heart failure
- randomized controlled trial
- clinical trial
- physical activity
- prognostic factors
- low dose
- cardiovascular disease
- high dose
- mesenchymal stem cells
- mechanical ventilation
- coronary artery disease
- birth weight
- patient reported